Vinorelbine
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Vinorelbine: From Non-Small Cell Lung Cancer to Ewing Sarcoma
One-Sentence Summary
Vinorelbine is a vinca alkaloid chemotherapy originally used for non-small cell lung cancer (NSCLC) and lung cancer. The TxGNN model predicts it may be effective for Ewing sarcoma, with 3 related clinical trials (two Phase 2 studies in relapsed or refractory paediatric tumours) and 6 publications currently supporting this direction. The evidence is indirect and comes mostly from mixed tumour populations.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Non-small cell lung carcinoma, lung cancer (from the TxGNN knowledge graph; the Singapore licence records contain no indication text) |
| Predicted New Indication | Ewing sarcoma |
| TxGNN Prediction Score | 99.999% |
| Evidence Level | L2 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the source database. Based on known pharmacology, vinorelbine is a vinca alkaloid that inhibits microtubule polymerisation. This causes mitotic arrest and apoptosis in rapidly dividing cells.
Ewing sarcoma is a rapidly proliferating small round cell sarcoma with high relapse rates, especially in multi-metastatic disease. Vinorelbine's efficacy in lung cancer is established, and its antimitotic action is not specific to one tumour type. When combined with low-dose metronomic cyclophosphamide, it has shown activity in relapsed or refractory Ewing sarcoma and other paediatric solid tumours.
Preclinical work also shows synergy between microtubule-interfering drugs, including vinorelbine, and PLK1 inhibition in Ewing sarcoma cells. A 2026 review rationalises vinorelbine plus low-dose cyclophosphamide as maintenance therapy in the international INTER-EWING-1 trial.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00003234 | Phase 2 | Completed | 50 | Vinorelbine in children with recurrent or refractory malignancies. Mixed paediatric tumour population, so Ewing-specific evidence is indirect. |
| NCT00180947 | Phase 2 | Unknown | 210 | Vinorelbine plus cyclophosphamide in refractory or relapsed tumours, including Ewing tumours, rhabdomyosarcoma, osteosarcoma, neuroblastoma and medulloblastoma. Results are unverified. |
| NCT06451302 | N/A | Active, not recruiting | 100 | Prospective cohort of risk-stratified treatment in paediatric Ewing sarcoma in China. Vinorelbine is not clearly the studied intervention, so relevance is low. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22633624 | 2012 | Phase 2 trial | Eur J Cancer | Vinorelbine plus continuous low-dose oral cyclophosphamide in children and young adults with relapsed or refractory solid tumours. Good tolerance, with efficacy noted in rhabdomyosarcoma. |
| 12115359 | 2002 | Phase 2 trial | Cancer | Vinorelbine in previously treated advanced childhood sarcomas, with activity shown in rhabdomyosarcoma. |
| 42561548 | 2026 | Systematic review (cohort data) | Cancer Treat Rev | Reviews the feasibility and rationale of maintenance therapy in Ewing sarcoma. Supports vinorelbine plus low-dose cyclophosphamide in the INTER-EWING-1 trial. |
| 37637411 | 2023 | Review | Front Pharmacol | Review of chemotherapy for soft tissue sarcomas. |
| 26260582 | 2016 | Preclinical | Int J Cancer | PLK1 inhibitor BI 6727 shows synergistic apoptosis with microtubule-interfering drugs, including vinorelbine, in Ewing sarcoma cells. |
| 36451163 | 2022 | Case report | BMC Urol | Extraosseous Ewing sarcoma of the kidney. Diagnostic focus, with limited relevance to vinorelbine. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN06778P | NAVELBINE INJECTION 10 mg/ml | Injection | Not stated in the licence record |
| SIN12547P | NAVELBINE SOFT CAPSULE 30 mg | Capsule, liquid filled | Not stated in the licence record |
| SIN12546P | NAVELBINE SOFT CAPSULE 20 mg | Capsule, liquid filled | Not stated in the licence record |
Both an injectable and an oral route are available in Singapore.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (vinca alkaloid, antimicrotubule agent) |
| Myelosuppression Risk | High. Myelosuppression is the dose-limiting toxicity of vinorelbine, and leukopenia appears among the contraindicated conditions in the knowledge graph. |
| Emetogenicity Classification | Low to moderate. Please confirm against the package insert. |
| Monitoring Items | CBC with differential, liver and renal function, and monitoring for neurotoxicity and respiratory symptoms |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
- Contraindicated conditions (knowledge graph, not label text): liver failure, infectious disease, ileus, intestinal obstruction, interstitial lung disease, lung disease, obsolete rare pulmonary disease, leukopenia.
- Drug interactions: 100 interactions were recorded. Examples:
- Major: clarithromycin.
- Moderate: aprepitant, dexamethasone, metronidazole, eliglustat, miconazole, rolapitant, rosuvastatin, simvastatin, tinidazole, glycerol phenylbutyrate.
- Minor: levofloxacin.
Several moderate interactions involve CYP3A4-related drugs (for example azole antifungals, aprepitant and clarithromycin). Review co-medications carefully before use.
Please refer to the package insert for the official warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Ewing sarcoma has the strongest evidence among the predicted indications, with Phase 2 data for vinorelbine plus cyclophosphamide in relapsed or refractory paediatric solid tumours, a 2026 review and a supporting preclinical study. However, the clinical data come from mixed tumour populations, one key trial has unknown status, and no Ewing-specific randomised evidence is available. Other predicted indications, such as benign lung tumours and gingival fibromatosis, are not supported by evidence and are not recommended.
To proceed, the following is needed:
- Singapore package insert warnings and contraindications (not yet available), plus approved indication text for the three licences
- Detailed mechanism of action data
- Ewing-specific efficacy data, for example results from INTER-EWING-1 or subgroup analyses of the Phase 2 trials
- Dosing and route selection for paediatric and young adult patients (injectable versus oral metronomic regimens)
- A safety monitoring plan covering myelosuppression, CYP3A4 interactions and organ function, delivered within a specialist paediatric oncology setting
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.